500
Participants
Start Date
September 12, 2024
Primary Completion Date
February 1, 2033
Study Completion Date
August 1, 2039
177Lu-PMSA-617
Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.
Standard of Care
ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest, Angers
NOT_YET_RECRUITING
Institut Bergonié, Bordeaux
NOT_YET_RECRUITING
CHRU Brest, Brest
NOT_YET_RECRUITING
Centre Francois Baclesse, Caen
NOT_YET_RECRUITING
CHU Henri Mondor, Créteil
NOT_YET_RECRUITING
Centre Georges-François Leclerc, Dijon
NOT_YET_RECRUITING
CHU Grenoble, Grenoble
NOT_YET_RECRUITING
Centre Léon Berard, Lyon
RECRUITING
Institut Paoli-Calmettes, Marseille
NOT_YET_RECRUITING
CHRU Nancy, Nancy
NOT_YET_RECRUITING
Centre Antoine Lacassagne, Nice
NOT_YET_RECRUITING
Hôpital Cochin, Paris
NOT_YET_RECRUITING
Hôpital Saint Louis, Paris
NOT_YET_RECRUITING
Institut Curie, Paris
RECRUITING
Centre Eugène Marquis, Rennes
NOT_YET_RECRUITING
Centre Henri Becquerel, Rouen
NOT_YET_RECRUITING
CHU Rouen, Rouen
NOT_YET_RECRUITING
Institut Curie, Saint-Cloud
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest, Saint-Herblain
NOT_YET_RECRUITING
CHU Saint Etienne, Saint-Priest-en-Jarez
NOT_YET_RECRUITING
ICANS, Strasbourg
NOT_YET_RECRUITING
IUCT Oncopole, Toulouse
NOT_YET_RECRUITING
CHRU Tours, Tours
NOT_YET_RECRUITING
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
RECRUITING
Gustave Roussy, Villejuif
Collaborators (1)
Novartis
INDUSTRY
UNICANCER
OTHER